{
    "clinical_study": {
        "@rank": "154547", 
        "acronym": "CARMET", 
        "arm_group": [
            {
                "arm_group_label": "Metformin", 
                "arm_group_type": "Experimental", 
                "description": "500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl \u00e1 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl \u00e1 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening)"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the study is to evaluate the effect of metformin on myocardial function, insulin\n      resistance and selected metabolic markers in patients with type 2 diabetes and heart failure\n      (HF+DM+) in a cross-over, randomized, placebo controlled trial.\n\n      Hypothesis:\n\n      Metformin treatment in HF+DM+ group will lead to better myocardial function and load\n      tolerance in comparison to placebo. The degree of improvement will be linked to selected\n      metabolic parameters."
        }, 
        "brief_title": "Cardioprotective and Metabolic Effects of Metformin in Patients With Heart Failure and Diabetes", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Insulin Resistance", 
            "Chronic Heart Failure"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Heart Failure", 
                "Insulin Resistance"
            ]
        }, 
        "detailed_description": {
            "textblock": "40 patients with HF and DM without previous diabetes treatment will be randomized into 2\n      groups (A succession: MET-placebo, B succession: placebo-MET) - stratified randomization\n      with following parameters weighted: HF etiology (ischemic /non-ischemic), diabetes duration,\n      gender, BMI, age, NYHA, smoker/non-smoker). After 3 months the treatment will be switched.\n      All participants will undergo standardized selection of metabolic and cardiovascular tests\n      (hyperinsulinemic euglycemic clamp with indirect calorimetry, measurement of endothelial\n      function, echocardiography, spiroergometry, proton/phosphor MR spectroscopy, adipose tissue\n      biopsy, selected cytokines in plasma and adipose tissue at the beginning and the end of each\n      intervention period (3 times in total)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. chronic heart failure will be defined by the following criteria (all must be\n             included):\n\n               -  diagnosis of HF known for at least 6 months\n\n               -  medical history of hospitalization for cardiac decompensation with need for\n                  parenteral therapy for congestion - X-ray findings or swelling of lower\n                  extremities\n\n               -  stable drug therapy at least 1 month\n\n               -  treatment with diuretics (thiazide or furosemide)\n\n               -  LVEF below 50%\n\n          2. the presence of diabetes will be defined by:\n\n               -  diagnosis and treatment of type 2 diabetes in the medical history\n\n               -  screening blood sample:\n\n                    -  the value of HbA1c(according to IFCC)\u2265 4.8% + fasting glucose \u2265 7.0 mmol /\n                       l in venous plasma or\n\n                    -  the value of HbA1c \u2265 4.8%(according to IFCC) + random blood glucose \u2265 11.1\n                       mmol/l in venous plasma\n\n                    -  or OGTT - blood glucose level at 120 min \u2265 11.1 mmol/l OGTT is indicated\n                       just in case of positivity of one of the criteria (fasting glucose + HbA1c\n                       or HbA1c + random blood glucose)\n\n               -  treatment of diabetes - by diet only\n\n               -  women and men aged 40-70 years\n\n               -  body mass index (kg/m2) in the range of 20-35\n\n               -  the range of HbA1c between 4-6,5% IFCC\n\n               -  signed informed consent\n\n        Exclusion Criteria:\n\n          1. the planned cardiac intervention during the study that affect the function of the\n             heart (revascularization including PCI, heart surgery, implantation of pacemaker, RF\n             ablation; urgent candidate for OTS\n\n          2. metabolic disease, including: 1 type diabetes, decompensated thyreopathy (Note:\n             patients with hypothyroidism and stable substitution (the last 3 months) of normal\n             TSH levels may participate in the study\n\n          3. treatment with insulin or PAD one month before the recruitment(patients who were\n             temporarily treated with insulin during hospitalization may participate in the study)\n\n          4. pregnancy (positive \u03b2-HCG test), breast feeding, trying to become pregnant\n\n          5. clinically significant anemia with hemoglobin below 100 g/l\n\n          6. renal insufficiency with eGF below 0.7 ml/s\n\n          7. atrial fibrillation - present during screening test\n\n          8. the presence of other medical condition, which occurs during physical examination,\n             laboratory tests, ECG, including pulmonary, neurological or inflammatory disease,\n             which would be considered by the examiner to distort the consistency of data"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01690091", 
            "org_study_id": "NT13034"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Metformin", 
                    "Placebo"
                ], 
                "description": "Patients will be randomized into 2 groups (A succession: MET-placebo, B succession: placebo-MET. After 3 months the treatment will be switched.\nTitration:\n500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl \u00e1 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening)", 
                "intervention_name": "Metformini hydrochloridum (Siofor 1000 tbl, Berlin)", 
                "intervention_type": "Drug", 
                "other_name": "A10BA02 Metformin"
            }, 
            {
                "arm_group_label": [
                    "Metformin", 
                    "Placebo"
                ], 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "chronic heart failure", 
            "type 2 diabetes", 
            "metformin", 
            "insulin resistance"
        ], 
        "lastchanged_date": "October 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Prague", 
                    "country": "Czech Republic"
                }, 
                "name": "Diabetes Center, Institute of Clinical and Experimental Medicine"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Czech Republic"
        }, 
        "number_of_arms": "2", 
        "official_title": "Cardioprotective and Metabolic Effects of Metformin in Patients With Heart Failure and Diabetes", 
        "overall_contact": {
            "email": "terezie.pelikanova@medicon.cz", 
            "last_name": "Terezie Pelikanova, Prof., MD", 
            "phone": "+420 261 364 100"
        }, 
        "overall_official": {
            "affiliation": "Diabetes Center, Institute of Clinical and Experimental Medicine", 
            "last_name": "Terezie Pelikanova, Prof., MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Czech Republic: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "change of glucose disposal during clamp", 
            "measure": "insulin sensitivity", 
            "safety_issue": "Yes", 
            "time_frame": "at baseline and after 3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01690091"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Institute for Clinical and Experimental Medicine", 
            "investigator_full_name": "Prof. Terezie Pelikanova", 
            "investigator_title": "Prof.MUDr.Terezie Pelikanova DrSc.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "change of energy expenditure measured by indirect calorimetry", 
                "measure": "energy expenditure", 
                "safety_issue": "Yes", 
                "time_frame": "at baseline and after 3 months"
            }, 
            {
                "description": "change in digital pulse amplitude tonometry", 
                "measure": "endothelial function", 
                "safety_issue": "Yes", 
                "time_frame": "at baseline and after 3 months"
            }, 
            {
                "description": "change measured by echocardiography and spiroergometry", 
                "measure": "heart function", 
                "safety_issue": "Yes", 
                "time_frame": "at baseline and after 3 months"
            }
        ], 
        "source": "Institute for Clinical and Experimental Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Institute for Clinical and Experimental Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}